Related Experiment Video
Updated: May 6, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
What evidence exists to support antiviral treatment in children with chronic hepatitis B?
Raffaele Iorio1, Maria Tufano, Maria G Giagnorio
1Department of Translational Medical Sciences, University of Naples Federico II, Naples, Italy.
Insights
Optimal management for children with chronic hepatitis B (HBV) remains unclear. Current therapies offer limited benefits and potential side effects, necessitating careful consideration against the disease's natural course.
Area of Science:
- Pediatric Hepatology
- Viral Hepatitis Management
- Infectious Diseases in Children
Background:
- Chronic hepatitis B (HBV) infection in children often presents as a mild condition.
- Current therapeutic interventions for pediatric HBV demonstrate partial efficacy, primarily in specific patient subgroups.
- Available antiviral drugs for chronic HBV lack proven long-term advantages over untreated disease and present numerous limitations.
Purpose of the Study:
- To critically appraise existing studies on the natural history of chronic hepatitis B in children.
- To evaluate the long-term outcomes of current therapeutic schedules for pediatric HBV infection.
- To inform decision-making regarding the balance between treatment benefits, side effects, and the natural disease progression.
Main Methods:
- Critical appraisal of published literature on pediatric chronic hepatitis B.
- Review of studies examining the natural history of HBV in children.
- Analysis of long-term data from therapeutic interventions in pediatric HBV cohorts.
Main Results:
- The optimal management strategy for chronically HBV-infected children is not well-defined.
- Therapeutic responses in pediatric HBV are often partial and subgroup-dependent.
- Available HBV treatments show limited proven benefit on the long-term disease course compared to no treatment.
Conclusions:
- A careful balance is required between the potential benefits and side effects of HBV treatment in children.
- The natural course of untreated chronic hepatitis B in children warrants consideration in management decisions.
- Further research is needed to establish evidence-based guidelines for pediatric HBV management.
Abstract:
Many questions are unanswered on the optimal management of chronically HBV-infected children. Chronic hepatitis B is generally a mild disease in children; however, response to therapy is partial and limited to specific subgroups, and available drugs have no proven advantage on long-term course of disease versus no treatment, and are hampered by numerous limitations. Studies on the natural history of chronic hepatitis B and the long-term results of the therapeutic schedules adopted so far should be critically appraised. A balance between the potential benefits of the treatment and its side effects, and the spontaneous course of the disease left untreated should be made.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
09:35Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
Published on: February 1, 2017
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Retrovirus Life Cycles
Pharmacokinetics in Pediatric Patients: Drug Excretion
Viruses with RNA Genomes